Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia

SETTING: Tomsk, Russia, where multidrug-resistant tuberculosis (MDR-TB) is prevalent.OBJECTIVES: To report rates of recurrence following successful treatment of MDR-TB in a program providing individualized treatment regimens designed according to the current global standard of care.DESIGN: A retrosp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The international journal of tuberculosis and lung disease 2015-04, Vol.19 (4), p.399-405
Hauptverfasser: Gelmanova, I. Y., Ahmad Khan, F., Becerra, M. C., Zemlyanaya, N. A., Unakova, I. A., Andreev, Y. G., Berezina, V. I., Pavlova, V. E., Shin, S., Yedilbayev, A. B., Krasnov, V. A., Keshavjee, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:SETTING: Tomsk, Russia, where multidrug-resistant tuberculosis (MDR-TB) is prevalent.OBJECTIVES: To report rates of recurrence following successful treatment of MDR-TB in a program providing individualized treatment regimens designed according to the current global standard of care.DESIGN: A retrospective cohort study of 408 adults successfully treated for pulmonary MDR-TB from 10 September 2000 to 1 November 2004, and followed for up to 6 years post-treatment. We used Poisson regression with generalized estimating equations to assess whether recurrence rates changed significantly with time.RESULTS: We analyzed 399 (97.5%) patients with at least one follow-up visit (15 850 person-months of observation [PMO]). Baseline resistance to second-line drugs was common (65.2%); 398 patients (99.7%) were human immunodeficiency virus (HIV) negative. In the first year of post-treatment follow-up, there were six episodes of recurrence (1.4/1000 PMO, 95%CI 0.5-3.0). After the first post-treatment year, there were 21 episodes of recurrence (1.8/1000 PMO, 95%CI 1.1-2.8). The rate did not change significantly with time.CONCLUSION: Individualized regimens designed according to the current global standard of care achieved low rates of MDR-TB recurrence among non-HIV-infected persons treated in a programmatic setting.
ISSN:1027-3719
1815-7920
DOI:10.5588/ijtld.14.0415